Celcuity (NASDAQ:CELC) Sets New 52-Week High – Here’s What Happened

Celcuity, Inc. (NASDAQ:CELC) shares reached a new 52-week high on Monday . The stock traded as high as $102.15 and last traded at $101.8880, with a volume of 248158 shares. The stock had previously closed at $97.50.

Analyst Upgrades and Downgrades

CELC has been the topic of several research analyst reports. Leerink Partners increased their price target on shares of Celcuity from $28.00 to $60.00 and gave the stock an “outperform” rating in a research report on Monday, July 28th. Stifel Nicolaus increased their target price on Celcuity from $68.00 to $115.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Craig Hallum lifted their target price on Celcuity from $96.00 to $108.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Wall Street Zen lowered Celcuity from a “hold” rating to a “sell” rating in a research report on Sunday, October 26th. Finally, Needham & Company LLC set a $95.00 price objective on Celcuity in a research note on Monday, October 20th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $97.00.

Celcuity Price Performance

The firm has a market capitalization of $4.68 billion, a price-to-earnings ratio of -27.56 and a beta of 0.72. The company has a current ratio of 12.26, a quick ratio of 12.26 and a debt-to-equity ratio of 2.74. The business has a 50-day moving average price of $65.17 and a two-hundred day moving average price of $40.06.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.92) EPS for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.13. As a group, research analysts forecast that Celcuity, Inc. will post -2.62 EPS for the current year.

Insider Activity at Celcuity

In related news, Director Richard E. Buller sold 3,900 shares of the stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $96.73, for a total value of $377,247.00. Following the sale, the director owned 7,260 shares of the company’s stock, valued at $702,259.80. This trade represents a 34.95% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 15.77% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of CELC. US Bancorp DE increased its stake in shares of Celcuity by 25.4% in the third quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after purchasing an additional 143 shares during the period. Rhumbline Advisers grew its holdings in Celcuity by 1.2% in the 2nd quarter. Rhumbline Advisers now owns 42,697 shares of the company’s stock worth $570,000 after buying an additional 503 shares in the last quarter. Ogorek Anthony Joseph NY ADV bought a new position in Celcuity in the 3rd quarter worth approximately $27,000. Intech Investment Management LLC increased its position in Celcuity by 5.2% in the 2nd quarter. Intech Investment Management LLC now owns 14,855 shares of the company’s stock valued at $198,000 after acquiring an additional 734 shares during the period. Finally, BNP Paribas Financial Markets raised its stake in Celcuity by 78.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock valued at $35,000 after acquiring an additional 1,167 shares in the last quarter. 63.33% of the stock is owned by institutional investors and hedge funds.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.